Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 9/20 | 1.00 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182938 | 1.00 | GRM7 (1.00) | GRM7LTB4RLTB4R2HDAC3HDAC1 | |
| SCHEMBL21542299 | 1.00 | GRM7 (1.00) | GRM7LTB4RLTB4R2HDAC3HDAC1 | |
| SCHEMBL21542214 | 0.86 | GRM7 (0.76) | GRM7LTB4RLTB4R2 | |
| SCHEMBL20182770 | 0.86 | GRM7 (0.76) | GRM7LTB4RLTB4R2 | |
| SCHEMBL21542216 | 0.86 | GRM7 (0.76) | GRM7LTB4RLTB4R2 | |
| SCHEMBL21542320 | 0.86 | GRM7 (0.75) | GRM7LTB4RLTB4R2 | |
| SCHEMBL20165982 | 0.86 | GRM7 (0.75) | GRM7LTB4RLTB4R2 | |
| SCHEMBL20165979 | 0.86 | GRM7 (0.75) | GRM7LTB4RLTB4R2 | |
| SCHEMBL20165981 | 0.86 | GRM7 (0.75) | GRM7LTB4RLTB4R2 | |
| SCHEMBL21542318 | 0.86 | GRM7 (0.75) | GRM7LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | claimed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | claimed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | claimed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | GRM7 1/4885LTB4R 863/4885LTB4R2 750/4885 |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | GRM7, GRM2, GRM1 | GRM7 1/4885LTB4R 863/4885LTB4R2 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.